10,800 Shares in Cullinan Oncology, Inc. (NASDAQ:CGEM) Acquired by Bailard Inc.

Bailard Inc. purchased a new stake in Cullinan Oncology, Inc. (NASDAQ:CGEM) in the 4th quarter, Holdings Channel.com reports. The fund purchased 10,800 shares of the company’s stock, valued at approximately $110,000.

Several other institutional investors also recently bought and sold shares of the business. SG Americas Securities LLC grew its position in shares of Cullinan Oncology by 12.3% in the fourth quarter. SG Americas Securities LLC now owns 14,449 shares of the company’s stock valued at $147,000 after purchasing an additional 1,587 shares during the period. Annandale Capital LLC boosted its stake in Cullinan Oncology by 20.0% in the 3rd quarter. Annandale Capital LLC now owns 12,000 shares of the company’s stock worth $109,000 after buying an additional 2,000 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in Cullinan Oncology by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 14,076 shares of the company’s stock valued at $143,000 after buying an additional 3,569 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Cullinan Oncology by 352.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,954 shares of the company’s stock valued at $50,000 after acquiring an additional 3,859 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Cullinan Oncology by 1,331.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,542 shares of the company’s stock worth $59,000 after acquiring an additional 6,085 shares during the period. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Jonestrading raised their target price on shares of Cullinan Oncology from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. William Blair started coverage on shares of Cullinan Oncology in a report on Monday, April 15th. They issued an “outperform” rating on the stock. HC Wainwright dropped their price objective on Cullinan Oncology from $34.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. BTIG Research increased their target price on Cullinan Oncology from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Wedbush initiated coverage on Cullinan Oncology in a research report on Thursday, February 15th. They set an “outperform” rating and a $30.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $28.75.

Cullinan Oncology Stock Up 7.2 %

Shares of CGEM stock opened at $27.12 on Tuesday. Cullinan Oncology, Inc. has a fifty-two week low of $7.64 and a fifty-two week high of $29.12. The firm’s 50 day moving average price is $17.50 and its two-hundred day moving average price is $13.21. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -7.35 and a beta of 0.33.

Cullinan Oncology (NASDAQ:CGEM) last issued its earnings results on Thursday, March 14th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.42. On average, equities analysts forecast that Cullinan Oncology, Inc. will post -3.21 EPS for the current fiscal year.

Insider Activity at Cullinan Oncology

In other Cullinan Oncology news, insider Corrine Savill sold 40,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $16.18, for a total transaction of $647,200.00. Following the transaction, the insider now owns 165,990 shares in the company, valued at $2,685,718.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.82% of the stock is owned by insiders.

About Cullinan Oncology

Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.